NCT02612285 2018-11-14
Study of SNX-5422 in TP53 Null Cancers
Esanex Inc.
Phase 2 Terminated
Clinical Trials
4 trialsNCT01848756 2017-02-09
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Esanex Inc.
Phase 1/2 Terminated
NCT01611623 2013-04-02
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Esanex Inc.
Phase 1 Completed
NCT00506805 2012-05-28
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Esanex Inc.
Phase 1 Completed